Matches in Wikidata for { <http://www.wikidata.org/entity/Q37667038> ?p ?o ?g. }
- Q37667038 description "article científic" @default.
- Q37667038 description "article scientifique" @default.
- Q37667038 description "articolo scientifico" @default.
- Q37667038 description "artigo científico" @default.
- Q37667038 description "artículu científicu espublizáu en 2017" @default.
- Q37667038 description "bilimsel makale" @default.
- Q37667038 description "scientific article published on 23 January 2017" @default.
- Q37667038 description "vedecký článok" @default.
- Q37667038 description "vetenskaplig artikel" @default.
- Q37667038 description "videnskabelig artikel" @default.
- Q37667038 description "vědecký článek" @default.
- Q37667038 description "wetenschappelijk artikel" @default.
- Q37667038 description "wissenschaftlicher Artikel" @default.
- Q37667038 description "наукова стаття, опублікована в січні 2017" @default.
- Q37667038 description "научни чланак" @default.
- Q37667038 description "مقالة علمية نشرت في 23 يناير 2017" @default.
- Q37667038 name "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 name "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 name "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 type Item @default.
- Q37667038 label "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 label "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 label "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 prefLabel "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 prefLabel "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 prefLabel "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 P1433 Q37667038-AFD49162-FDB6-4D44-B8D6-A5E040BBA278 @default.
- Q37667038 P1476 Q37667038-F986BB6C-D8D5-4169-B89B-8CB30AB5A951 @default.
- Q37667038 P2093 Q37667038-0C80F84F-73BC-4BE7-A57A-882F77EFAE03 @default.
- Q37667038 P2093 Q37667038-11395582-9EF7-43CC-B8CB-393EFA40FDD0 @default.
- Q37667038 P2093 Q37667038-3F9D2D40-6149-48BC-BCC2-BA7BF577C703 @default.
- Q37667038 P2093 Q37667038-4080FA0B-207E-48A9-8735-134CB00FB9D5 @default.
- Q37667038 P2093 Q37667038-58D20D28-F5A6-4B1A-BD61-9CE8C04CF2A7 @default.
- Q37667038 P2093 Q37667038-6807BE79-60BA-4EA9-91DE-5CA7B27A7A59 @default.
- Q37667038 P2093 Q37667038-6D73E4D3-DFEC-4880-9FC5-B095C137A1DB @default.
- Q37667038 P2093 Q37667038-7B610002-FE24-49F8-A3E0-36E5E1C7C9B6 @default.
- Q37667038 P2093 Q37667038-7C359FDC-8CAA-4BD0-8694-433341A9B124 @default.
- Q37667038 P2093 Q37667038-7D39DE9D-7CB9-4EF2-8324-00F6B1882E5A @default.
- Q37667038 P2093 Q37667038-97110E0C-462E-40C3-8F53-913D0A7D5E74 @default.
- Q37667038 P2507 Q37667038-7CCD2029-6EBC-4668-A1F5-E4D10E003658 @default.
- Q37667038 P2860 Q37667038-00A93A03-D2DE-499E-9E57-9AADDB967259 @default.
- Q37667038 P2860 Q37667038-042AAB1B-88E1-42D4-AF7B-AF174E560AD2 @default.
- Q37667038 P2860 Q37667038-0B6F267E-029A-4BF3-ABB9-DF2E3B069B09 @default.
- Q37667038 P2860 Q37667038-132DD8AC-696B-44F1-8F95-CD0FB7408ABF @default.
- Q37667038 P2860 Q37667038-195E7822-12B9-4C32-9848-FA1F75FB3E31 @default.
- Q37667038 P2860 Q37667038-3D0B1C39-7805-4EAA-B856-B5520086E9BB @default.
- Q37667038 P2860 Q37667038-40A06568-F07F-4857-BB89-E18332EC894D @default.
- Q37667038 P2860 Q37667038-54A050D6-CCCA-4A07-B0C5-0FDD5F56F250 @default.
- Q37667038 P2860 Q37667038-583A411B-3E25-4216-9BE9-E7DE99C2C829 @default.
- Q37667038 P2860 Q37667038-679A985F-615F-45DA-B4DA-86623643E855 @default.
- Q37667038 P2860 Q37667038-7A11C282-AC79-48E8-B5EE-C35D2867B790 @default.
- Q37667038 P2860 Q37667038-7B1D6075-9F60-45D0-AF86-366D9B107BA1 @default.
- Q37667038 P2860 Q37667038-80486775-3FE8-428D-8169-E40746A4F74F @default.
- Q37667038 P2860 Q37667038-8060FF3C-D418-4E09-A566-B63407489CF0 @default.
- Q37667038 P2860 Q37667038-82AB70A5-C131-477E-8D39-27B2C94C62CA @default.
- Q37667038 P2860 Q37667038-84EC0885-7AFC-4C2B-AC4E-E631C6A0DD8D @default.
- Q37667038 P2860 Q37667038-8C496D49-E8D2-4ED4-A05F-5614C560FF93 @default.
- Q37667038 P2860 Q37667038-8F37AA2D-5EF7-4662-94D0-A65F8FF85C3C @default.
- Q37667038 P2860 Q37667038-98EA41CA-2C60-4058-8FF8-D6127A5BDD4D @default.
- Q37667038 P2860 Q37667038-9E9F0DB1-CA5F-4FB1-963F-4F759F3D34FE @default.
- Q37667038 P2860 Q37667038-A1B051F6-55A0-4707-9954-F0433B730BCA @default.
- Q37667038 P2860 Q37667038-A451AC71-3640-41CA-BF1B-AC4AD13E11A7 @default.
- Q37667038 P2860 Q37667038-A4998B5B-5298-47C6-BDE0-D904822EFBBE @default.
- Q37667038 P2860 Q37667038-B48C0424-15C3-4C32-BABE-F94BAB7D0E5B @default.
- Q37667038 P2860 Q37667038-B7E758C6-FD18-4C21-8416-C3D869F3878D @default.
- Q37667038 P2860 Q37667038-BD4C2B4D-B438-4C38-9E92-8606AB267D76 @default.
- Q37667038 P2860 Q37667038-C592DB28-F7E9-41E3-81F1-D84863679037 @default.
- Q37667038 P2860 Q37667038-C9597ABC-5058-4399-BF78-58F8A3650516 @default.
- Q37667038 P2860 Q37667038-CCC13F00-AAD7-446D-8607-A9CA5B1652C2 @default.
- Q37667038 P2860 Q37667038-D563690C-8FC4-4607-9F1E-BA5930C8A5B5 @default.
- Q37667038 P2860 Q37667038-DCF8BF7B-9E4B-4376-991A-EF7A21554112 @default.
- Q37667038 P2860 Q37667038-DDB48B87-A4B3-4B52-B627-723C6370ED90 @default.
- Q37667038 P2860 Q37667038-E605FB5C-DCBE-455A-B0AE-2F085941D3F7 @default.
- Q37667038 P2860 Q37667038-E8F6AF89-41B6-496C-BBFF-79586866CBAE @default.
- Q37667038 P2860 Q37667038-F977470D-228A-43B6-A00D-3AC9BCD1EC84 @default.
- Q37667038 P2860 Q37667038-FA6CA04F-AE25-4976-818C-61DE3231F03E @default.
- Q37667038 P2888 Q37667038-5B943213-EE19-4B48-99E2-D6D009D2D639 @default.
- Q37667038 P304 Q37667038-EA43E71C-0E1C-4356-8DE5-897DBED42098 @default.
- Q37667038 P31 Q37667038-6BA9CE5D-1C7C-4167-BA52-65F7A60039FD @default.
- Q37667038 P356 Q37667038-45452536-4A31-4751-8D95-BD7132197E33 @default.
- Q37667038 P407 Q37667038-40144B56-97F7-4736-8EB2-51468AB4660F @default.
- Q37667038 P433 Q37667038-A7BFF7C4-D553-404C-984A-F24DBCB777C3 @default.
- Q37667038 P478 Q37667038-772B579D-ED46-4BF5-8755-35B7E99F2251 @default.
- Q37667038 P50 Q37667038-0ACD82CB-992B-42E9-B50C-5006880F041F @default.
- Q37667038 P50 Q37667038-4F821A2A-F942-4FDD-B055-CCAE05ED4D01 @default.
- Q37667038 P50 Q37667038-9548391F-D9DE-4373-AEC3-D64C4E1548E2 @default.
- Q37667038 P50 Q37667038-D41888AE-D0C0-4320-9592-3FF0E3FD62FB @default.
- Q37667038 P50 Q37667038-DD6D28A7-C4FA-400C-B786-730766A400B6 @default.
- Q37667038 P50 Q37667038-E0D3DEC9-7220-487D-B42F-41D34A087883 @default.
- Q37667038 P50 Q37667038-EDF3511E-AAA2-4D42-9E6A-1A0214C0F28A @default.
- Q37667038 P50 Q37667038-FC25C82A-E752-42CC-A6C4-B880DF3A07E3 @default.
- Q37667038 P577 Q37667038-030A72BA-EDFC-4F9D-A2C2-EF02A3958A52 @default.
- Q37667038 P698 Q37667038-8C00D4B4-D7DD-4373-BCFF-BF9C848ED888 @default.
- Q37667038 P921 Q37667038-35275C7B-F7C2-4775-BAE4-8AD2B347F9F0 @default.
- Q37667038 P932 Q37667038-4B413380-C4C1-4444-846C-8C04AABA7725 @default.
- Q37667038 P356 NG.3773 @default.
- Q37667038 P698 28112739 @default.
- Q37667038 P1433 Q976454 @default.
- Q37667038 P1476 "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer" @default.
- Q37667038 P2093 "Giacomo Corleone" @default.